Research progress on tumor-targeting paclitaxel prodrugs
10.3969/j.issn.1006-0111.2018.01.001
- VernacularTitle:靶向肿瘤微环境的紫杉醇前药研究进展
- Author:
Dan CHENG
1
;
Youfa XU
;
Zhiqin FU
;
Jianming CHEN
Author Information
1. 第二军医大学药学院药剂学教研室
- Keywords:
paclitaxel prodrug;
tumor microenvironment;
targeting;
antitumor
- From:
Journal of Pharmaceutical Practice
2018;36(1):1-8
- CountryChina
- Language:Chinese
-
Abstract:
Paclitaxel is a natural compound with efficient broad-spectrum antitumor activity .However ,the clinical ap-plication has been limited owing to the undesirable drawbacks ,such as the poor water-solubility ,cardiovascular toxicity and neurotoxicity .The design of paclitaxel prodrugs is an effective measure which can improve the drug's druggability ,alleviate its toxicity adverse effect and enhance its antitumor effect .With the in-depth research of prodrugs ,tumor-targeting paclitaxel pro-drugs which using the excessive receptors ,specific enzymes ,transporters ,reactive oxide species ,glutathione in tumor tissues as well as acidosis and hypoxia in tumors as specific targets ,have made great progress .The relevant literature about paclitaxel prodrugs were reviewed in this paper ,which targeted to the specific pathological and physiological features of tumor microenvi-ronment in recent years.
